Besremi (ropeginterferon alfa-2b-njft) for Essential thrombocythemia

PharmaEssentia · sBLA

Approved

The FDA approved this application. Approval is the starting line, not the finish: our guide to what happens in the 90 days after a rare disease approval walks through specialty pharmacies, insurance review, and how families shorten the wait.

What is being decided

PharmaEssentia has a sBLA under FDA review for Besremi (ropeginterferon alfa-2b-njft) in Essential thrombocythemia. Label expansion into essential thrombocythemia.

Who this decision matters to

Essential Thrombocythemia is a myeloproliferative neoplasm characterized by overproduction of platelets by bone marrow, resulting in very high platelet counts. Patients are at increased risk for blood clots and, paradoxically, bleeding complications. Many cases involve mutations in JAK2, CALR, or MPL genes.

Prevalence: Approximately 1-2 cases per 100,000 people; median age of diagnosis is 60 years. See our full Essential Thrombocythemia page for current treatments, recruiting trials, and community resources.

Where Essential Thrombocythemia treatment stands today

Research in Essential Thrombocythemia is evolving toward personalized treatment strategies that account for your specific genetic makeup and risk profile. Clinical trials are testing targeted JAK inhibitors, HDAC inhibitors, and innovative agents designed to reduce platelet production while preserving quality of life and keeping side effects manageable. Understanding your mutation status, genetic risk, and individual clot and bleeding risk allows your hematologist to tailor therapy specifically to your situation. Hydroxyurea has long been standard treatment for platelet reduction, but emerging agents offer alternatives that may work better for some patients with fewer side effects. Discussing trial opportunities with your hematologist is an important part of developing a comprehensive treatment plan suited to your needs.

Meanwhile, 55 Essential Thrombocythemia trials are recruiting

Whatever the FDA decides here, research on Essential Thrombocythemia does not stop. A few currently enrolling studies, US sites first:

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

NCT07357727 · has US sites

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

NCT05320198 · has US sites

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

NCT07623200 · has US sites

See all 55 recruiting trials →

Get the news the day the FDA decides

One email when the Besremi decision lands, with what it means in plain language. No newsletter, no spam.

Get trial alerts

Get notified when new essential-thrombocythemia trials open or existing trials change status, add sites, or update eligibility.

We never share your email. Unsubscribe anytime.

Frequently asked questions

When will the FDA decide on Besremi?

The FDA has already decided: the application was approved. See the outcome details above.

What is Besremi being reviewed for?

PharmaEssentia submitted a sBLA for Besremi in Essential thrombocythemia. Label expansion into essential thrombocythemia.

What happens after the Besremi decision?

If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.

Where this date comes from

The FDA does not publish PDUFA dates; companies disclose them. This one comes from CheckRare. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified weekly.